MedTrace Logo

Pegteograstim in Children With Solid Tumors

NCT02787876 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2018-09-18

No results posted yet for this study

Summary

To evaluate the efficacy and safety of pegteograstim on chemotherapy-induced neutropenia in children with solid tumors

Conditions

  • Chemotherapy Induced Neutropenia
  • Pediatric Solid Tumor

Interventions

DRUG

Pegteograstim

Sponsors & Collaborators

  • Green Cross Corporation

    collaborator INDUSTRY

  • Samsung Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-04
Primary Completion
2018-10-31
Completion
2018-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02787876 on ClinicalTrials.gov